BioNTech (BNTX) PT Lowered to $95 at TD Cowen

Canaccord Genuity Reviews BioNTech (BNTX) Post Earnings

March 21, 2024 7:29 AM EDT

Canaccord Genuity analyst William Maughan reiterated a Buy rating and $171.00 price target on BioNTech (NASDAQ: BNTX).

The analyst comments "Shares of BNTX are down 8% (-1% NBI) today after BioNTech presented FY23/4Q23 results. FY23 revenue of 3.8B was roughly in line with previous guidance of 4B, while FY24 guidance was updated to 2.5-3.1B (prev. ~3B). Both of those updates are incrementally below previous expectations, which... More

BioNTech (BNTX) PT Lowered to $123 at BMO Capital

March 21, 2024 6:31 AM EDT

BMO Capital analyst Etzer Darout lowered the price target on BioNTech (NASDAQ: BNTX) to $123.00 (from $127.00) while maintaining a Outperform rating.

The analyst comments "BNTX reported FY23 revenues of 3.8B vs. our 4.3B and FY24 revenue guidance of 2.53.1B vs. our 3.1B. While BNTX's financial... More

BioNTech (BNTX) PT Lowered to $91 at Goldman Sachs

March 21, 2024 4:48 AM EDT

Goldman Sachs analyst Chris Shibutani lowered the price target on BioNTech (NASDAQ: BNTX) to $91.00 (from $100.00) while maintaining a Neutral rating.

The analyst comments "BNTX reported 4Q23 earnings with Comirnaty (COVID-19 vaccine) sales coming in below expectations (1.48bn vs GS/Visible Alpha Consensus Data... More

JPMorgan Continues to See 2024 AS an 'execution year' for BioNTech (BNTX)

March 20, 2024 2:37 PM EDT

JPMorgan analyst Jessica Fye reiterated a Neutral rating and {REMOVEPT} price target on BioNTech (NASDAQ: BNTX)

The analyst comments "We continue to view 2024 as an execution year for BNTX with an aim to set the company up to achieve its longer-term goals (e.g., targeting... More

Midday movers: Mobileye, Chipotle rise; Signet, BioNTech fall

March 20, 2024 8:12 AM EDT

(Updated - March 20, 2024 11:26 AM EDT)

Investing.com -- Main U.S. indexes were flat Wednesday, with investors wary ahead of the latest Federal Reserve monetary policy decision.

Here are some of the biggest U.S. stock movers today:

Nvidia (NASDAQ: NVDA) stock fell 0.5% in volatile trading after the chipmaker revealed pricing and shipment plans for its hotly anticipated Blackwell B200 chip.

Intel (NASDAQ: INTC) stock rose 0.6% after the Biden administration announced it is... More

Moderna (MRNA) Trades Lower in Sympathy with BioNTech (BNTX)

March 20, 2024 7:09 AM EDT

Moderna (NASDAQ: MRNA) Trades Lower in Sympathy with BioNTech SE (NASDAQ: BNTX)

BioNTech -5.5% After EPS Misses ConsensusModerna -2%... More

BioNTech SE (BNTX) Misses Q4 EPS by 46c, Misses on Revenue; Offers FY24 Revenue Guidance

March 20, 2024 6:19 AM EDT

BioNTech SE (NASDAQ: BNTX) reported Q4 EPS of EUR1.90, EUR0.46 worse than the analyst estimate of EUR2.36. Revenue for the quarter came in at EUR1.48 billion versus the consensus estimate of EUR2.02 billion.

For full year 2024 the company sees revenue of 2.5 billion to 3.1 billion... More

After earnings plunge, BioNTech pins hopes on cancer drug launches

March 20, 2024 6:17 AM EDT

By Ludwig Burger

BERLIN (Reuters) -Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, reported on Wednesday a plunge in 2023 revenue and earnings as its focus shifts towards cancer drug development.

The Mainz-based company posted revenues of 3.819 billion euros ($4.14 billion), down by more than... More

BioNTech SE (BNTX) Appoints Annemarie Hanekamp as Chief Commercial Officer

March 20, 2024 6:00 AM EDT

BioNTech (Nasdaq: BNTX) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024. She will join BioNTech from Novartis AG (Novartis) and succeed Sean Marett in this role.

Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing... More